Inhibikase Therapeutics, Inc.

As of August 12, 2022, Inhibikase Therapeutics, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics, including a P/B ratio of 1.70 and poor year-to-date performance, with a decline of 48.92%.

As of June 11, 2025, Inhibikase Therapeutics, Inc. is in a bearish trend with moderate strength, supported by bearish signals from the MACD, moving averages, Bollinger Bands, and KST on the weekly chart.

Inhibikase Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $14 million and a market cap of $129.35 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -43.99%.

As of Jun 18, Inhibikase Therapeutics, Inc. has a market capitalization of 129.35 million, with net sales of 0.00 million and a net profit of -36.55 million over the latest four quarters. The company reported shareholder's funds of 94.87 million and total assets of 98.60 million as of Dec 24.